Use of recombinant granulocyte-macrophage colony stimulating factor in the Brazil radiation accident.
8 patients with bone marrow failure after a caesium-137 radiation accident were treated with recombinant human granulocyte-macrophage colony stimulating factor (rHuGM-CSF). The 7 who were evaluable had prompt increases in granulocytes and bone marrow cellularity. 2 patients died of radiation toxicity and haemorrhage and 2 of bacterial sepsis acquired before the start of rHuGM-CSF treatment. 4 patients survive, including 2 who were treated early and never became infected. This therapeutic approach to radiation-induced granulocytopenia may therefore be useful after radiation and nuclear accidents.
D000059:Accidents; D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000380:Agranulocytosis / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D001938:Brazil; D002588:Cesium Radioisotopes / Q000009:adverse effects*; D002648:Child; D003115:Colony-Stimulating Factors / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D004781:Environmental Exposure; D004866:Equipment Contamination; D005260:Female; D005507:Food Contamination, Radioactive; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D006133:Growth Substances / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011829:Radiation Dosage; D011832:Radiation Injuries / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D011850:Radioactive Waste / Q000009:adverse effects; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D013997:Time Factors
D002588:Cesium Radioisotopes; D003115:Colony-Stimulating Factors; D006133:Growth Substances; D011850:Radioactive Waste; D011994:Recombinant Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor